Dry Age-Related Macular Degeneration

Primary Investigator: Andre Witkin, MD

Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration

Sponsor: Genentech

Brief Summary
This is a Phase III study evaluating the efficacy and safety of intravitreal lampalizumab, compared to sham injections, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Inclusion/Exclusion Criteria
Well-demarcated area(s) of GA secondary to AMD with no evidence of prior or active choroidal neovascularization (CNV) in either eye

Study Length and Visits: 2-year study with additional testing

Age Range: 50+ years

Gender: Both

Payment: $50 per visit

*Transportation provided

Contact: Carly Satsuma, 617-636-5489